Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy

Loading news article.

Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy | WAPE

Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy

Article summary

Related companies

Comments —